title: Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.
abstract: Development of recurrent platinum resistant disease following chemotherapy presents a challenge in managing ovarian cancer. Using tumors derived from genetically defined mouse ovarian cancer cells, we investigated the stem cell properties of residual cells post-chemotherapy. Utilizing CD133 and Sca-1 as markers of candidate tumor initiating cells (TIC), we determined that the relative levels of CD133+ and Sca-1+ cells were unaltered following chemotherapy. CD133+ and Sca-1+ cells exhibited increased stem cell-related gene expression, were enriched in G0/G1-early S phase and exhibited increased tumor initiating capacity, giving rise to heterogeneous tumors. Our findings suggest that residual TICs may contribute to recurrent disease.
authors.affiliation: Vincent Center for Reproductive Biology, Department of Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Kashmira
authors.initials: K
authors.lastname: Kulkarni-Datar
authors.forename: Sandra
authors.initials: S
authors.lastname: Orsulic
authors.forename: Rosemary
authors.initials: R
authors.lastname: Foster
authors.forename: Bo R
authors.initials: BR
authors.lastname: Rueda
mesh_terms: D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D000950:Antigens, Ly / Q000235:genetics / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016190:Carboplatin / Q000008:administration & dosage / Q000494:pharmacology*; D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004195:Disease Models, Animal; D005260:Female; D015870:Gene Expression; D006023:Glycoproteins / Q000235:genetics / Q000378:metabolism; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology*; D010455:Peptides / Q000235:genetics / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D000950:Antigens, Ly; D000970:Antineoplastic Agents; D006023:Glycoproteins; C074650:Ly6a protein, mouse; D008565:Membrane Proteins; D010455:Peptides; C000606024:Prom1 protein, mouse; D016190:Carboplatin; D017239:Paclitaxel
keywords: CD133 cells; Ovarian cancer tumor initiating cells; Sca-1 cells